Active, not recruitingPhase 2NCT04278781
AG-120 in People With IDH1 Mutant Chondrosarcoma
Studying Chondrosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Ciara M Kelly, MBBCh, BAOMemorial Sloan Kettering Cancer Center
- Intervention
- AG-120(drug)
- Enrollment
- 6 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2026
Study locations (5)
- Johns Hopkins Hospital (Data Collection Only), Baltimore, Maryland, United States
- Columbia University (Specimen Analysis Only), New York, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- The Ohio State University (Data Collection Only), Columbus, Ohio, United States
- MD Anderson Cancer Center (Data Collection Only), Houston, Texas, United States
Collaborators
Agios Pharmaceuticals, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04278781 on ClinicalTrials.govOther trials for Chondrosarcoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNANCT07360964Clear Cell Chondrosarcoma in ItalyIstituto Ortopedico Rizzoli
- RECRUITINGNCT07315542Diagnostic and Therapeutic Targets in Cartilaginous TumoursSt. Anne's University Hospital Brno, Czech Republic
- RECRUITINGEARLY PHASE1NCT06645808PET-imaging of Two Vartumabs in Patients With Solid TumorsVar2 Pharmaceuticals
- RECRUITINGPHASE3NCT06127407Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment RegimenServier Bio-Innovation LLC
- RECRUITINGNCT06486506Proximal Femur Reconstruction Following Resection of Primary Bone Tumors: Analysis of the Clinical and Radiographic ResultsCostantino Errani
- RECRUITINGPHASE2NCT06176989Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base TumorsNational Cancer Institute (NCI)
- RECRUITINGNANCT06387485A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative PlanningRicoh USA, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT05836571Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue SarcomaNational Cancer Institute LAO